Many cancer referral guidelines use patient's age as a key criterium to decide who should
be referred urgently. A recent rise in the incidence of colorectal cancer in younger adults has …

Bladder cancer (BCa) is among the ten most frequent cancers globally. It is the tumor with
the highest lifetime treatment‐associated costs, and among the tumors with the heaviest …

Background Previous studies have reported on incidence and mortality patterns for
individual genitourinary cancers in the USA. However, these studies addressed individual …

Simple Summary Bladder cancer is a complex disease, the sixth most common cancer, and
one of the most expensive cancers to treat. In the last few decades, there has been a …

Purpose To provide an overview of fibroblast growth factor receptor (FGFR) gene alterations
and the pharmacology, clinical effectiveness, dosage and administration, cost, and place in …

Simple Summary Bladder cancer (BC) is a common cancer that causes high morbidity and
mortality among affected patients. As a carcinogen-driven cancer, molecular oncology of BC …

The management of urothelial carcinoma (UC) has rapidly advanced in recent years with
new approvals for immune checkpoint inhibitors and antibody-drug conjugates. However …

Bladder cancer (BC), a common urologic cancer, is the fifth most frequently diagnosed tumor
worldwide. hsa‑miR‑34a displays antitumor activity in several types of cancer. However, the …

Squamous cell carcinomas are therapeutically challenging tumor entities. Low response
rates to radiotherapy and chemotherapy are commonly observed in squamous patients and …

Background Information about survival by stage in bladder cancer is scarce, as well as
about survival of non-invasive bladder cancer. The aims of this study are: 1) to find out the …